anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses an oral care solution used after neurosurgical operation. Raw materials of the oral care solution comprise, by weight, 40-50 parts of Magnolia officinalis, 20-30 parts of Semen Ziziphi Spinosae, 10-20 parts of Radix Astragali, 10-20 parts of Dendrobium, 20-30 parts of Portulaca oleracea, 20-30 parts of Potentilla discolor, 10-20 parts of Houttuynia cordata, 30-40 parts of Corydalis bungeana, 20-30 parts of Fructus Gardeniae, 20-30 parts of Prunella vulgaris, 3-10 parts of Viola japonica and 10-20 parts of green tea. The invention also discloses a preparation method of the oral care solution. The oral care solution of the invention has stable performance, can refresh oral cavity, effectively inhibit and kill harmful bacteria in the oral cavity and prevent accumulation and reproduction of bacterial plaque. Then, oral diseases such as bad breath, gum swelling and hemorrhage, etc. can be effectively prevented, a good oral environment is maintained, and the probability of postoperative complications is reduced.
Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredient: 14.0% Benzocaine (USP = 28 mg). Administered in a single anesthetic spray. Tested over a 60 minute session. Used in Stage I of the study only.
<P>PROBLEM TO BE SOLVED: To support execution of input work which puts a smaller load on an operator who inputs a prescription order.  <P>SOLUTION: The disease name of a patient is obtained. Out of a disease name-classified prescription history data base 202 storing disease names, medicine identifiers for identifying medicines, and the total number of prescriptions of the medicine made by a plurality of doctors for the disease names in association with one another, the medicine identifier and the total number of prescriptions associated with the obtained disease name are extracted as first extraction information. Out of a doctor-classified prescription history data base 203 storing the medicine identifiers and the individual number of times of prescriptions made by a doctor in association with one another, for each doctor identifier for identifying the doctor who prescribes to the patient among a plurality of doctors, the medicine identifier and the individual number of times of prescriptions associated with the doctor identifier are extracted as second extraction information. On the basis of the first extraction information and the second extraction information, a display method in displaying medicine identifiers on a display device 116 that the doctor views is determined.  <P>COPYRIGHT: (C)2011,JPO&INPIT
FIELD: medicine.SUBSTANCE: invention relates to medicine, specifically to ophthalmology. For conducting ultrasonic cross-linking in progressive keratoconus in patients with initial corneal thickness at apex of cone ≤ 400 mcm after deepithelialization, a patient's corneal thickness is measured by intraoperative optical coherence tomography (OCT). Corneal protector solution used is dextralink, which is instilled onto the patient's cornea for 30 minutes. After that, in the course of repeated OCT, the corneal pachymetry is determined in the thinnest place and the protective cornea protective flap thickness is calculated as difference between 400 mcm and the minimum pachymetry value of the patient's cornea according to the repeated OCT data. At that, to obtain a protective flap of a layer of the anterior donor stroma of the native donor cornea, which is resected with a femtolaser, of the required thickness with diameter of 9.4 mm, a donor sclerotic strain disc is used, isolated by means of a femtoscopic laser from a native cadaver's eye, pre-used in parallel to femtoscopic posterior layer keratoplasty or Descemet's membrane transplantation on one operation day. After the femtosecond resection of the native donor corneal stroma layer and obtaining a protective flap, it is separated from the underlying tissues, laid on the patient's corneal surface and centered. That is followed by the control intraoperative OCT of the "patient's cornea - donor cornea stroma flap" complex to confirm the total thickness of at least 400 mcm. Then ultraviolet irradiation is carried out patient procedure through the protective corneal stroma of a donor cornea flap wavelength 370 nm capacity of 9 mW/cmfor 10 minutes with parallel dextralink instillation every 2 min. After irradiation, a protective flap of donor cornea stroma is removed.EFFECT: method provides the safe procedure of ultraviolet cross-linking by replenishing the corneal thickness deficiency of the patient to the required value taking into account individual values of patient's thin corneal pachymetry, absence of intra- and postoperative complications, strengthening of strength properties of the cornea, stopping and absence of keratoconus progression in the remote postoperative period.1 cl, 1 ex
BACKGROUND: No proven treatment after the development of primary graft dysfunction (PGD) is currently available. Here, we established a novel strategy of in vivo lung perfusion (IVLP) for the treatment of PGD. IVLP involves the application of an in vivo isolated perfusion circuit to an implanted lung. This study aimed to explore the effectiveness of IVLP vs conventional post-lung transplant (LTx) extracorporeal membrane oxygenation (ECMO) treatment using an experimental swine LTx PGD model.
METHODS: After 1.5-hour warm ischemia of the donor lungs, a left LTx was performed. Following the confirmation of PGD development, pigs were divided into 3 groups (n = 5 each): control (no intervention), ECMO, and IVLP. After 2 hours of treatment, a 4-hour functional assessment was conducted, and samples were obtained.
RESULTS: Significantly better oxygenation was achieved in the IVLP group (p ≤ 0.001). Recovery was confirmed immediately and maintained during the following 4-hour observation. The IVLP group also demonstrated better lung compliance than the control group (p = 0.045). A histologic evaluation showed that the lung injury score and terminal deoxynucleotidyl transferase dUTP nick end labeling assay showed significantly fewer injuries and a better result in the wet-to-dry weight ratio in the IVLP group.
CONCLUSIONS: A 2-hour IVLP is technically feasible and allows for prompt recovery from PGD after LTx. The posttransplant short-duration IVLP strategy can complement or overcome the limitations of the current practice for donor assessment and PGD management.
Participants in yoga group will be recruited during prenatal yoga classes at two locations: Maribor and Ljubljana. Women will be instructed to attend one class per week. Classes will consist of pregnancy-adapted yoga practices according to the system Yoga in Daily Life. They will be 90 min in duration and will consist of initial relaxation (10 to 15 min), followed by yoga postures (asanas) and stretching exercises (45 to 60 min), and final breathing (pranayama), concentration (dharana), and meditation (dhyana) techniques (20 to 30 min). Two certified yoga instructors will lead yoga classes. Measurements will be performed before and after yoga session.
BACKGROUND: The presence of cancer cachexia is a significant adverse prognostic indicator in patients with malignant tumors. Cancer cachexia is a multifactorial syndrome characterized by a constant loss of skeletal muscles with or without a loss of weight, leading to immune dysfunction. We performed a retrospective study to investigate the influence of cachexia on the immunotherapy efficacy and prognosis for malignant tumors of the digestive system.
METHODS: The present study adopts a cross-sectional design. The prognosis data of patients with advanced cancer of the digestive system who received immunotherapy from September 2021 to December 2022 were analyzed. Cachexia was calculated using the change of the area of the psoas major muscle (PMMA) or the weight. We measured the change at the beginning of immunotherapy and at least 2 cycles afterward. The participants were categorized into the cachexia group and control group based on the evaluation criteria. Kaplan-Meier and Log-rank methods were used for survival analysis. Cox proportional hazard model as a method to assess the contribution of different clinical factors to overall survival (OS) and progression-free survival (PFS).
RESULTS: A total number of 98 patients, including esophageal carcinoma (4, 4%), gastric (36, 37%), colorectal (51, 52%), and other cancer types (7, 7%), were enrolled. Fifty-four patients were diagnosed with non-cancer cachexia, and the cancer cachexia group included 44 patients. The median PFS in the cachexia group was shorter than that in the control group (130 days vs. 212 days). Their difference was not significant (p = .321). The survival rate of the patients without cachexia was longer than of those with cachexia (p = .027). The level of albumin and the number of metastatic organs were related to PFS (p = .020, p = .029). The albumin level was significantly associated with the OS of patients (p = .003).
CONCLUSIONS: The presence of cachexia was significantly associated with poor OS in patients with malignant tumors of the digestive system who received immunotherapy, not with PFS or the response to immunotherapy.
The extract is useful for oral or parenteral treatment of intestinal disorders, opt. with associated hepatic disorders, such as diarrhoea, cholecystitis, renal lithiasis, gout and pancreatitis. Dose is usually 2 g. daily for 10 days. The extract is not toxic to mice at 8 g/kg orally. In vitro, it is active against amoebae, Lamtha, Trichomonas and Chilomastix. In vivo, the extract has a sedative and analgesic action, is a general tonic and is active in the intestinal and urinary tracts.
Each participant received a 0.5 mL IM injection for 7 to 11 months of age (PCV-naïve)(3 doses). Dose 1: at randomization, Dose 2: 4 to 8 weeks after Dose 1, and Dose 3: 8 to 12 weeks after Dose 2 and ≥12 months of age.
To simulate the scenario of infant CPR, an ALS Baby trainer manikin (Laerdal Medical, Stavanger, Norway) simulating a 3-month-old infant. The manikin was connected with a fixed-volume arterial system attached to a monitor (Draeger Infinity® Delta; Draegerwerk AG \& Co. KGaA, Luebeck, Germany) via an arterial pressure transducer (Edward Lifesciences: TruWave Disposable Pressure Transducer; Irvine, CA, USA). The arterial circuit composed of a 50-mL bag of normal saline solution (air removed) attached to the manikin chest plate and connected to the transducer with a 20-gauge intravenous catheter and tubing. The manikin was placed on a high adjustable hospital stretcher. The bed was leveled to the iliac crest of each rescuer for standardization. The manikin was previously intubated and ventilation was performed using a resuscitator bag.
Up to 9 dose levels in total will be evaluated across two dosing schedules. Eligible patients will be assigned to a dose level cohort according to an accelerated titration design that will transition to a traditional 3+3 dose escalation.
The invention discloses a kind of grape pip extract powder production technology：1. first oil pressure is squeezed out typically to squeeze out 12 15% or so with the physical method of oil press before extracting；2. it is again that quality is hard, than heavy, to become quality after squeezing loose for the seed of poor fluidity during extraction, the dregs of rice of light specific gravity, the dregs of rice extract stirring when bottom suitably inflation with regard to above and below energy, left and right uniformly seethe, be conducive to accelerating the release and release of active ingredient complete, shorten extraction time, recovery rate also brings up to the 85% of the dregs of rice from the 70% of original seed；3. it need to be extracted 4 times from original seed, and the dregs of rice need to only be extracted 2 times；4.5m is added when extracting every time 3 Solvent, by it is each reclaim loss 10% based on, reduce by 2 solvent recovery 9m 3 , reduce and waste 0.9m 3 ；4. by often reclaiming 1m 3 Solvent consumption 0.5m 3 Vaporimeter, reclaims No. 2 meter 9m less 3 , reduce steam 4.5m 3 ；The additive that the grape pip fat come is also used as animal feed is squeezed out, waste resource is retrieved utilization.
OBJECTIVE: Numerous articles and reviews addressing the intersection of Chronic Obstructive Pulmonary Disease (COPD) with sarcopenia have been documented. However, a significant gap exists in the literature concerning scientometric analysis in this field. This study aimed to concentrate on recent research and elucidate emerging research areas through the examination of COPD with sarcopenia.
METHODS: Articles in the field were systematically retrieved from the Web of Science Core Collections (WoSCC) spanning from 2003 to 2022. The analysis employed scientometric and keyword analyses through specialized software, including VOSviewer, CiteSpace, and Origin.
RESULTS: A comprehensive analysis of 758 articles and reviews in the field of COPD with sarcopenia revealed the United States as the leading contributor in terms of publications and overall influence. Maastricht University emerged as the most prolific institution, with Schols Annemie M. W. J. being identified as the most influential scholar in this field. The International Journal of Chronic Obstructive Pulmonary Disease emerged as the most prolific journal. Notably, COPD with sarcopenia exhibits frequent associations with other diseases, underscoring the complexity of the topic and emphasizing the necessity for comprehensive treatment. Mechanistic and diagnostic aspects, particularly computed tomography, are pivotal in this research field. Osteoporosis emerges as a prospective avenue for future research, encompassing both COPD and sarcopenia. Furthermore, nutrition and physical activity are integral components for managing COPD patients with sarcopenia.
CONCLUSION: This study delineates the distribution of fields, the knowledge structure, and the evolution of major research topics related to COPD with sarcopenia. The identification of keyword hotspots enhances the understanding of the occurrence, development, and future study trends associated with the topic.
<P>PROBLEM TO BE SOLVED: To establish IL-11 (interleukin-11) having an added sugar chain and a method for producing the same for aiming at the modification of the IL-11 and to provide a medicinal composition comprising the IL-11.  <P>SOLUTION: The IL-11 is modified by adding the sugar chain. Furthermore, the sugar chain is selected from sugar chains of an N type sugar chain, an O type sugar chain and a combination of N type and O type. A protein composed of an amino acid sequence in which one or several amino acids are deleted, substituted, added or modified, having the IL-11 activity and receiving the addition of the sugar chain is included in the IL-11 for adding the sugar chain in which a signal peptide represented by database is cleaved. In the IL-11, the sugar chain is preferably bound to a site without greatly changing the three-dimensional structure by addition of the sugar chain or in the vicinity of the N-terminal or C-terminal.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
HYDREA is used alone or in conjunction with other antitumor agents or radiation therapy to treat neoplastic diseases. Individualize treatment based on tumor type, disease state, response to treatment, patient risk factors, and current clinical practice standards.

Base all dosage on the patient's actual or ideal weight, whichever is less.

HYDREA is a cytotoxic drug. Follow applicable special handling and disposal procedures [see References (15)].

Swallow HYDREA capsules whole. Do NOT open, break, or chew capsules because HYDREA is a cytotoxic drug.

Prophylactic administration of folic acid is recommended [see Warnings and Precautions (5.8)].

Monitor blood counts at least once a week during HYDREA therapy. Severe anemia must be corrected before initiating therapy with HYDREA.
The invention belongs to the technical field of fluorescent probes, and discloses a tricyclic 2-aminopyridine salt fluorescent probe and a preparation method and application thereof. The structure of the fluorescent probe of the tricyclic 2-aminopyridine salt is shown as a formula I, wherein: r 1 ，R 2 Independently are aryl, heteroaryl, C 1‑18 Alkyl radical, C 3‑8 Electron donating groups of cycloalkyl or aromatic ring derivatives; x is a monovalent anion; m is an integer of 0 to 2; n is any integer of 0 and 1. The invention also discloses a preparation method of the fluorescent probe. The fluorescent probe has aggregation-induced emission property, can realize rapid dyeing identification of microorganisms, and embodies the characteristics of specificity, high efficiency and sensitivity. The fluorescent probe has excellent bacteriostatic effect. The fluorescent probe is used for preparing reagents for specifically dyeing mitochondria and dyeing microbes with negative charges on the surface, and is also used for preparing reagents for distinguishing the death and activity states of the microbes and antibacterial agents. 。
PURPOSE: To prepare a solidified capsule without destroying the hermetic sealing and engagement of the capsule by liquefying a mixture containing an ingestible matrix having the melting point within a specific range and an oral administration medicament, filling the resultant liquefied mixture in the capsule, solidifying the mixture and integrating the mixture with the capsule. CONSTITUTION: A flowable mixture containing an orally administrable medicament in an ingestible matrix having a melting point up to 100 deg.C (e.g. carbohydrates, polyalkylene glycols or polyoxyalcohols) is prepared and the resultant mixture is then heated and liquefied. The liquefied mixture is subsequently introduced into an ingestible hollow capsule to substantially completely fill the mixture in the interior of the capsule. The resultant capsule is then hermetically sealed to solidify the mixture in the hermetically sealed capsule. Thereby, a solidified encapsulated product in which the mixture is mutually integrated with the capsule is obtained. Polyethylene glycol having 6,000-10,000 molecular weight alone or a mixture thereof with gelatin or sorbitol or mannitol is preferred as the matrix.
This will be a single-site study aimed at evaluating the safety, tolerability, and efficacy of quetiapine as compared to placebo in the treatment of generalized anxiety disorder. This will be an 8-week open-label sertraline trial followed by a randomized double-blind placebo-controlled, parallel-group prospective study. Participants will first receive sertraline (25-200 mg/day) for 8 weeks. Patients who remain symptomatic - are considered refractory - and meet inclusion criteria will be randomized and enter the double-blind phase. They will receive either adjunctive quetiapine (25-400 mg/day) or placebo for 8 weeks. The primary outcome measures are change in the Liebowitz Social Anxiety Scale(LSAS) and Clinical Global Impression of Improvement (CGI-I) scores. The proposed sample size is 80 subjects. Patients will be discontinued from the study if needed due to ineffectiveness or excessive side effects. Measurements of changes in efficacy and side effects will be carried out every weekly visit. Enrollment will occur over 12 months.
The intervention group participated in a mindfulness-based structured nursing interventions program planned for a total of eight days, 60 minutes each day, led by Elçin Alaçam, who has a Mindfulness Institute-approved certificate. The mindfulness-based structured nursing interventions program was structured for 8 days, taking into account the literature and the characteristics of high-risk pregnant women such as length of hospitalization.
BACKGROUND: Postoperative sore throat (POST) is a common complaint after general anesthesia. POST is defined by the presence of a self-reported foreign body sensation or a painful sensation in the throat after general anesthesia. This condition may affect recovery and patient satisfaction and is associated with many factors, including intubation tools. Previous studies have reported conflicting results on POST. This retrospective cohort study, with sample size of 9,881 patients, was conducted to confirm the hypothesis that the use of video laryngoscopy (VL) is associated with a lower incidence of POST compared with direct laryngoscopy (DL).
METHODS: Data were extracted from a prospectively maintained quality improvement database. A total of 9,881 patients were included in the study. Statistical analysis was conducted for comparisons of demographic characteristics and to determine the effect of intubation tools on the incidence of POST.
RESULTS: The patients had similar baseline demographic characteristics. Compared with DL, VL was associated with a lower incidence of POST (12.98% vs. 17.49%, P < 0.001). In addition, the use of Pentax Airway Scope (AWS) was associated with a lower incidence of POST compared with the use of GlideScope (GVL, 8.14% vs. 16.25%, P < 0.001). To better adjust for possible confounding factors, mixed-effects generalized linear model analysis revealed that older age (odds ratio [OR]: 0.995, 95% confidence interval [CI]: 0.992-0.999, P = 0.006), AWS compared to DL (OR: 0.416, 95% CI: 0.350-0.494, P < 0.001), and male sex (OR: 0.836, 95% CI: 0.747-0.935, P = 0.002) are associated with reduced incidence of POST.
CONCLUSION: Compared with DL, VL is associated with a lower incidence of POST. In addition, the use of AWS is associated with a lower incidence of POST compared with the use of GVL.
TRIAL REGISTRATION: Retrospectively registered, NCT06515808, date of registration: 23/07/2024.
BACKGROUND: This study aimed to assess the associations of orthostatic hypotension (OH), in the presence or absence of frailty, with dementia and mortality in older adults.
METHODS: We conducted a 15-year population-based cohort study including 2 703 baseline dementia-free individuals from the Swedish National Study on Aging and Care in Kungsholmen. At baseline, OH was defined as a decline in systolic/diastolic blood pressure ≥20/10 mm Hg 1 minute after standing up from a supine position. Frailty status was defined following Fried's frailty phenotype. Dementia was diagnosed following the Diagnostic and Statistical Manual of Mental Disorders-fourth edition criteria. Multistate flexible parametric survival models were used to estimate associations of OH and frailty with dementia and mortality.
RESULTS: Robust people with OH (adjusted hazard ratio [HR] = 2.28; 95% confidence interval [CI] = 1.47-3.54) and frail people without OH (HR = 1.98; 95% CI = 1.40-2.82) or with OH (HR = 2.73; 95% CI = 1.82-4.10) had a higher dementia risk than OH-free and robust people. Moreover, frail people, independently of the presence of OH, had higher mortality rate than OH-free and robust people. In individuals who developed dementia during the follow-up period, neither OH nor frailty was significantly associated with mortality.
CONCLUSIONS: Older adults with OH, whether robust or frail, may have a higher dementia risk than those without OH. Older adults with OH, when having frailty, may have a higher mortality rate than those without OH. The concurrent assessments of OH and frailty may provide prognostic values in terms of dementia and mortality risk in older adults.